About Xenon Pharmaceuticals Inc. Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of ...
Xenon ( ($XENE) ) has provided an announcement. Xenon Pharmaceuticals Inc. announced that President and CEO Ian Mortimer will present a company ...
– Phase 3 azetukalner X-TOLE2 FOS study patient recruitment expected to complete in the next few months with topline data anticipated in early 2026 – Phase 3 azetukalner X-NOVA3 MDD and Phase 3 BPD ...
Detailed price information for Xenon Pharmaceuticals Inc (XENE-Q) from The Globe and Mail including charting and trades.
– Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch – First of three planned Phase 3 azetukalner MDD studies ...
VANCOUVER, British Columbia and BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and ...
Biohaven didn't receive the clinical readout it was hoping for over the festive period. | As the biopharma wound down for the ...
VANCOUVER, British Columbia and BOSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback